Project Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 abiraterone abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T clinical trial crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy theranostics
Latest Posts
- Newsletter 11/2026 March 15, 2026
- Blood Lipid Profiles in Metastatic Prostate Cancer: A Window into Tumor Metabolism and Response to Enzalutamide March 14, 2026
- Organoids from Routine TUR‑P Samples: A Personalized Platform for Prostate Cancer Therapy Testing March 13, 2026
- Estrogen‑Based Androgen Suppression Plus ARSI in Prostate Cancer: A Phase 2 Quality‑of‑Life Trial March 13, 2026
The Promise of In Vivo CAR T Cell Therapies
/in Not PCa related/by MaxPlant Virus-Based Cancer Immunotherapy: A New Frontier in Fighting Cancer
/in Oncolytic, Preclinical Research/by MaxPSA Level at 6 Months as a Predictor of Long-Term Outcomes: Real 10-Year Overall Survival Data from the CHAARTED Trial
/in Post-hoc/by MaxAlpha DaRT: A Promising Frontier in the Treatment of Prostate, Bladder, and Advanced Cancers
/in Clinical Trial, Localized, Metastatic/by MaxStatins Linked to Improved Survival in Advanced Prostate Cancer Patients on Apalutamide
/in Post-hoc, Retrospective studies/by MaxOMNIRAY: a Phase 1 Clinical Trial for LY4257496 for mCRPC
/in Clinical Trial, Metastatic, Phase 1/by MaxThe OMNIRAY trial will be investigating LY4257496, a novel radioligand therapy and it is set to begin in August 2025. This phase 1a/1b, multicenter, open-label study aims to establish the safety, tolerability and dosimetry of LY4257496 in adult patients bearing advanced solid tumors that express the gastrin-releasing peptide receptor (GRPR). The trial proposes a two-part […]
Nutrition and Inflamation: New Research Unveils Five Universal Patient Clusters in Oncology
/in Retrospective studies/by MaxNuanced Benefits of Fasting-Mimicking Diets: High Protein vs. Low Protein
/in Clinical Trial/by MaxA recent study published in Clinical Nutrition sheds new light on the physiological impacts of Fasting-Mimicking Diets (FMDs), revealing that while both low-protein and high-protein versions offer significant health advantages, their specific benefits can differ notably. This randomized controlled trial explored the effects of a 7-day plant-based FMD with either a low protein/high fat (LP-FMD) […]